Three-month safety data from a Phase I clinical trial in China for Cellular Biomedicine’s AlloJoin™ off-the-shelf allogeneic stem cell therapy in the treatment of knee osteoarthritis demonstrated a safety and tolerability profile of AlloJoin in the three doses tested, with adverse events similar to that of earlier autologous trials. The trial is slated for completion in 3Q17.

Strategic orthopaedic-related 510(k)s issued in November 2016 include: Preference Elite Pedicle Screw System (Amedica); Titanium Porous Fixation Device (Amorchem); Moss 100 Pedicle Screw System (Biedermann Motech); Persona Partial Knee (Biomet/Zimmer Biomet); AltiVate Anatomic Shoulder, Exprt Revision Hip (Encore Medical/DJO); Initia Total Hip & Bioceram AZUL Head (Kyocera Medical); Virtu C Spinal Implant (Met 1); Interference Screw (Nanova Biomaterials); Fortezza Spinal Stabilization System (Osso Surgical)

Contact Us

0